In the final installment of this series, Dr. Diana Martinez navigates the process for receiving NIH funding to test the efficacy of using transcranial magnetic stimulation as treatment for cocaine addiction.
Investigators have shown that 2-AG, an endocannabinoid (i.e., a cannabinoid manufactured within the body, as opposed to plant-derived), augments the cocaine-induced dopamine surge in the brain’s reward system.
The discovery adds to evidence that inhibiting activity in the endocannabinoid system might reduce cocaine’s rewarding and addictive effects.
Drugs can alter the way people think, feel, and behave by disrupting neurotransmission, the process of communication between brain cells. This article discusses the central importance of studying drugs’ effects on neurotransmission and describes some of the most common experimental methods used in this research.
New studies show that two novel compounds powerfully suppressed animals’ pain responses, while producing little or none of the respiratory depression and liability for misuse and abuse associated with morphine and other typical opioids.
Researchers monitored the activity of two types of neurons in mice: “urge” neurons, which promote feelings of reward and repeating behaviors that have produced rewards, and “control” neurons, which dampen those feelings and inhibit behavior.
A new study proposes that research into the discrete roles played by the brain’s two hemispheres could yield important and actionable insights into drug use and addiction. Evidence indicates that two risk factors for substance use, impulsivity and craving, primarily reflect activity in the right and left hemispheres, respectively.
A brain imaging study strongly suggests that regular users of marijuana have smaller orbitofrontal cortex (OFC) volumes. Such a deficit could make it more difficult to change counterproductive behaviors, including drug use.